Vivos Therapeutics (NASDAQ:VVOS) had its price target lowered by analysts at Ascendiant Capital Markets from $6.50 to $5.50. They now have a "buy" rating on the stock.
Vivos Therapeutics (NASDAQ:VVOS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... [Yahoo! Finance]
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 [Yahoo! Finance]
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025